cyclance vet 100 mg/ ml
virbac - ciklosporin - mikstur, oppløsning - 100 mg/ ml
balance 1,5% glukose + 1,25 mmol ca/l
fresenius medical care deutschland gmbh - glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumlaktat / kalsiumkloriddihydrat - peritonealdialysevæske - 1.5 %
balance 2,3% glukose + 1,75 mmol ca/l
fresenius medical care deutschland gmbh - glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumlaktat / kalsiumkloriddihydrat - peritonealdialysevæske - 2.3 %
balance 2,3% glukose + 1,25 mmol ca/l
fresenius medical care deutschland gmbh - glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumlaktat / kalsiumkloriddihydrat - peritonealdialysevæske - 2.3 %
balance 4,25% glukose + 1,75 mmol ca/l
fresenius medical care deutschland gmbh - glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumlaktat / kalsiumkloriddihydrat - peritonealdialysevæske - 4.25 %
balance 4,25% glukose + 1,25 mmol ca/l
fresenius medical care deutschland gmbh - glukosemonohydrat / magnesiumkloridheksahydrat / natriumklorid / natriumlaktat / kalsiumkloriddihydrat - peritonealdialysevæske - 4.25 %
balance 1,5% glukose + 1,75 mmol ca/l
fresenius medical care deutschland gmbh - natriumklorid / natriumlaktat / kalsiumkloriddihydrat / magnesiumkloridheksahydrat / glukosemonohydrat - peritonealdialysevæske - / 1.5 %
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaksiner - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. bruk av denne vaksinen skal være i samsvar med offisielle anbefalinger.
mekinist
novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-small cell lung cancer (nsclc)trametinib i kombinasjon med dabrafenib er indisert for behandling av voksne pasienter med avansert non-small cell lung cancer med en braf v600 mutasjon.
zelboraf
roche registration gmbh - vemurafenib - melanom - antineoplastiske midler - vemurafenib er indisert i monoterapi for behandling av voksne pasienter med braf-v600-mutasjons-positiv, uoppløselig eller metastatisk melanom.